Number: GOG 261 Principal Investigator: Mutch, David
Title: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versis Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Phase: III Disease Site: Multiple Sites
Participating Site(s):
Contact: 800-600-3606 or

The purpose of this study is to compare the drugs carboplatin and paclitaxel to a standard treatment for your type of cancer (paclitaxel plus ifosfamide and mesna). Based on results of other clinical trials, researchers think that the combination of carboplatin and paclitaxel may be as effective as the combination of ifosfamide and paclitaxel with fewer side effects. In this study you will get either the combination of paclitaxel and carboplatin or the combination of ifosfamide and mesna plus paclitaxel. You will not get both combinations. Mesna is a protective medication and not an anti-cancer chemotherapy.
More Information:
Internal Protocol Documents (requires Siteman administrative database password)